Abstract:Ali A Ghweil, 1 Heba A Osman, 1 Mohammed H Hassan, 2 Abeer MM Sabry, 3 Reem E Mahdy, 4 Ahmed RH Ahmed, 5 Ahmed Okasha, 6 Ashraf Khodeary, 7 Hesham H Ameen 8 1 Tropical Medicine and Gastroenterology Department, Faculty of Medicine, South Valley University, Qena, Egypt; 2 Department of Medical Biochemistry, Faculty of Medicine, South Valley University, Qena, Egypt; 3 Internal Medicine and Gastroenterology Department, Faculty of Medicine, Helwan University, Helwan, Egypt; 4 Internal Medicine Department, Faculty of Medicine, Assiut University, Assiut, Egypt; 5 Pathology Department, Faculty of Medicine, Sohag University, Sohag, Egypt; 6 Radiology Department, Faculty of Medicine, South Valley University, Qena, Egypt; 7 Clinical Pathology Department, Faculty of Medicine, Sohag University, Sohag, Egypt; 8 Clinical Pathology Department, Faculty of Medicine, Al-Azhar University (Assiut Branch), Assiut, Egypt Correspondence: Mohammed H Hassan Department of Medical Biochemistry, Faculty of Medicine, South Valley University, Qena 83523, Egypt Tel +20 109 847 3605 Email mohammedhosnyhassaan@med.svu.edu.eg Background and aim: Gastric carcinomais a frequent neoplasm with poor outcome, and its early detection would improve prognosis. This study was designed to evaluate the possible use of new biomarkers, namely SAA and HMGB1, for early diagnosis of gastric cancer. Methods: A total of 100 patients presenting with gastric symptoms were included. All patients underwent upper endoscopic evaluation, histopathological diagnosis and serum CEA, SAA, and HMGB1 measurements. Results: Patients were classed endoscopically with neoplastic, inflammatory, and normal-appearing gastric mucosa: 50, 25, and 25 patients, respectively. Histologically, half the patients had chronic gastritis and the remaining cases gastric carcinoma of diffuse (n=28) or intestinal (n=22) type. SAA at cutoff of 18.5 mg/L had the best validity to differentiate gastritis from gastric carcinoma, with AUC, sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) of 0.99, 98%, 100%, 100%, and 98%, respectively, followed by HMGB1 at cutoff of 14.5 pg/μL, with AUC, sensitivity, specificity, PPV, and NPV of 0.91, 70%, 96%, 94.6%, and 76.2%, respectively. Sensitivity, specificity, PPV, and NPV of serum CEA at cutoff of 2.9 ng/mL to differentiate gastritis from gastric carcinoma were 42%, 72%, 60%, and 55.4%, respectively, with AUC of 0.53. Nonetheless, higher serum levels of both SAA and HMGB1 reflected higher tumor grade ( P =0.027 and P =0.016, respectively) and advanced tumor stage ( P -OBrk-0.001 for both). Conclusion: Serum levels of both SAA and HMGB1 could be of great value for early diagnosis of gastric carcinoma, comparable to the diagnostic role of serum CEA, which is not valid for early diagnosis of gastric cancer. Keywords: gastric carcinoma, early detection, SAA, HMGB1, CEA

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the early diagnosis of gastric cancer. Specifically, the research aims to evaluate the effectiveness of serum amyloid A (SAA) and high - mobility group box 1 (HMGB1) as biomarkers for the early diagnosis of gastric cancer. ### Background and Objectives Gastric cancer is a common malignant tumor with a poor prognosis, especially when it is detected at an advanced stage. Therefore, early detection is crucial for improving the prognosis of patients. Currently, the biomarkers used for the diagnosis and prognosis of gastric cancer have low sensitivity and specificity, and mainly rely on invasive upper gastrointestinal endoscopy. In order to find more effective non - invasive or minimally invasive biomarkers, this study selected SAA and HMGB1 as candidate markers for evaluation. ### Methods The study included 100 patients with gastric symptoms. All patients underwent upper gastrointestinal endoscopy, histopathological diagnosis, and measurement of serum CEA, SAA, and HMGB1 levels. The diagnostic performance of these biomarkers in distinguishing between chronic gastritis and gastric cancer was analyzed by receiver operating characteristic curve (ROC curve). ### Results - **SAA**: At a cut - off value of 18.5 mg/L, the area under the curve (AUC) of SAA for distinguishing between gastritis and gastric cancer was 0.99, with a sensitivity of 98%, a specificity of 100%, a negative predictive value (NPV) of 100%, and a positive predictive value (PPV) of 98%. - **HMGB1**: At a cut - off value of 14.5 pg/μL, the AUC of HMGB1 was 0.91, with a sensitivity of 70%, a specificity of 96%, a PPV of 94.6%, and an NPV of 76.2%. - **CEA**: At a cut - off value of 2.9 ng/mL, the AUC of CEA was only 0.53, with a sensitivity of 42%, a specificity of 72%, a PPV of 60%, and an NPV of 55.4%. In addition, higher serum SAA and HMGB1 levels were significantly associated with higher tumor grades ($P = 0.027$ and $P = 0.016$) and more advanced tumor stages ($P < 0.001$). ### Conclusions Serum SAA and HMGB1 are of great value in the early diagnosis of gastric cancer, and their diagnostic performance is superior to that of the traditional CEA marker. This indicates that SAA and HMGB1 may become effective tools for early screening of gastric cancer. ### Formula Summary - **AUC (Area Under the Curve)**: \[ \text{AUC}=\frac{\sum_{i = 1}^{N}(\text{sensitivity}_i+\text{sensitivity}_{i - 1})\times(\text{1 - specificity}_i-\text{1 - specificity}_{i - 1})}{2} \] - **Sensitivity**: \[ \text{Sensitivity}=\frac{\text{TP}}{\text{TP}+\text{FN}} \] - **Specificity**: \[ \text{Specificity}=\frac{\text{TN}}{\text{TN}+\text{FP}} \] - **Positive Predictive Value (PPV)**: \[ \text{PPV}=\frac{\text{TP}}{\text{TP}+\text{FP}} \] - **Negative Predictive Value (NPV)**: \[ \text{NPV}=\frac{\text{TN}}{\text{TN}+\text{FN}} \] where TP represents true positive, TN represents true negative, and F

Validity of serum amyloid A and HMGB1 as biomarkers for early diagnosis of gastric cancer

Serum biomarker panels for diagnosis of gastric cancer

Evaluation of serum markers for gastric cancer and its precursor diseases among high incidence and mortality rate of gastric cancer area

The Role of Biomarkers in the Early Diagnosis of Gastric Cancer: A Study on CCR5, CCL5, PDGF, and EphA7

Evaluation of tumor-associated antigen (2H6 antigen) in detecting early stages of gastric cancer

Serum phospholipids are potential biomarkers for the early diagnosis of gastric cancer

[Detection of Serum Endothelial Cell Specific Molecule 1 in Gastric Cancer Patients and Its Clinical Significance].

The clinical significance of some serum tumor markers among chronic patients with Helicobacter pylori infections in Ibb Governorate, Yemen

Application of serum gastric function markers and digestive tumor indices to the diagnosis of early gastric cancer and precancerous lesions

Validation of a blood biomarker for identification of individuals at high risk for gastric cancer.

112 Identification and Validation of Serum MicroRNA Biomarker for Early Detection of Gastric Cancer

[Diagnostic Value of Serum Pepsinogen Ⅰ/Pepsinogen Ⅱ Combined with Tumor Markers for Helicobacter pylori-Positive Early-Stage Gastric Cancer]

Small molecules as potential biomarkers of early gastric cancer: A mass spectrometry imaging approach

High Levels of Aromatic Amino Acids in Gastric Juice During the Early Stages of Gastric Cancer Progression

Diagnostic value of PLS-DA model of serum CA72-4,CA242,CA19-9 and CEA for gastric cancer

Serum Biomarkers AFP, CEA and CA19-9 Combined Detection for Early Diagnosis of Hepatocellular Carcinoma.

Serum Amyloid A is a Novel Prognostic Biomarker in Hepatocellular Carcinoma.

Preliminary study on proteomics of gastric carcinoma and its clinical significance.

[Advances in Serum Biomarkers for Early Diagnosis of Gastric Cancer].

Value of Serological Biomarker Panel in Diagnosis of Atrophic Gastritis and Helicobacter pylori Infection

Evaluation of squamous cell carcinoma antigen-immunoglobulin M complex (SCCA-IGM) and alpha-l-fucosidase (AFU) as novel diagnostic biomarkers for hepatocellular carcinoma